Publications
| Title | Abstract | Year(sorted descending) Filter | PMID Filter |
|---|
| infection and cancer: the case of hepatitis b. | infection is a well-described cause of cancer in humans. being one of the most common infections worldwide, hepatitis b virus (hbv) is the leading cause of hepatocellular carcinoma (hcc), particularly in asian countries. the etiological link between hbv and hcc provides an important opportunity for health care policy makers and clinicians to intervene with hbv infection to prevent cancer development and improve the outcomes of cancer. this review aims to use hbv as an example to illustrate the p ... | 2016 | 26578611 |
| abnormality of wnt3a expression as novel specific biomarker for diagnosis and differentiation of hepatocellular carcinoma. | the member 3a of wingless-type mmtv integration site family (wnt3a) as an oncogene is overexpressed in many kinds of tumors with a worse outcome. however, the mechanism and alteration of wnt3a expression in hepatocellular carcinoma (hcc) have not been clarified. in this study, the levels of wnt3a expression were investigated in 80 hcc tissues or sera of 186 patients with chronic liver diseases. the incidence of hepatic wnt3a expression in hcc tissues was 96.25 % and significantly higher (χ (2) = ... | 2016 | 26577850 |
| evidence that hepatitis b virus replication in mouse cells is limited by the lack of a host cell dependency factor. | hepatitis b virus (hbv) is a major human pathogen restricted to hepatocytes. expression of the specific receptor human sodium taurocholate cotransporting polypeptide (hntcp) in mouse hepatocytes renders them susceptible to hepatitis delta virus (hdv), a satellite of hbv; however, hbv remains restricted at an early stage of replication. this study aims at clarifying whether this restriction is caused by the lack of a dependency factor or the activity of a restriction factor. | 2016 | 26576481 |
| effects of hepatitis b surface antigen (hbsag) positivity of donors in hbsag(+) renal transplant recipients: comparison of outcomes with hbsag(+) and hbsag(-) donors. | the aim of this study was to determine the effects of hepatitis b surface antigen (hbsag) positivity of the donors on graft survival and liver complications in hbsag(+) renal transplant recipients. | 2016 | 26565663 |
| antiviral therapy in chronic hepatitis b viral infection during pregnancy: a systematic review and meta-analysis. | perinatal or mother-to-child transmission (mtct) of hepatitis b virus (hbv) remains the major risk factor for chronic hbv infection worldwide. in addition to hepatitis b immune globulin and vaccination, oral antiviral therapies in highly viremic mothers can further decrease mtct of hbv. we conducted a systematic review and meta-analysis to synthesize the evidence on the efficacy and maternal and fetal safety of antiviral therapy during pregnancy. a protocol was developed by the american associat ... | 2016 | 26565396 |
| the serum anti-hbs level among children who received routine hepatitis b vaccination during infancy in mianyang city, china: a cross-sectional study. | hepatitis b virus (hbv) prevalence has declined remarkably in children due to nationwide universal vaccination program for hbv in china. however, the persistence of immune response against hbv infection and the optimal time point when a booster vaccination should be performed remain to be elucidated. to assess the persistence and level of antibody against hepatitis b surface antigen (anti-hbs) in a representative population of age 15 and younger who received routine hepatitis b vaccination in mi ... | 2016 | 26565951 |
| asian-pacific clinical practice guidelines on the management of hepatitis b: a 2015 update. | worldwide, some 240 million people have chronic hepatitis b virus (hbv), with the highest rates of infection in africa and asia. our understanding of the natural history of hbv infection and the potential for therapy of the resultant disease is continuously improving. new data have become available since the previous apasl guidelines for management of hbv infection were published in 2012. the objective of this manuscript is to update the recommendations for the optimal management of chronic hbv ... | 2016 | 26563120 |
| health profiles of newly arrived refugee children in the united states, 2006-2012. | we conducted a large-scale study of newly arrived refugee children in the united states with data from 2006 to 2012 domestic medical examinations in 4 sites: colorado; minnesota; philadelphia, pennsylvania; and washington state. | 2016 | 26562126 |
| antiviral natural products against chronic hepatitis b: recent developments. | hepatitis b virus (hbv) is inherently a hepatotropic virus that causes acute and chronic hepatitis in about one-third of world population. of the estimated 360 million chronically infected individuals, more than one million die of liver cirrhosis, fulminant liver failure or hepatocellular carcinoma (hcc) every year. though there is an effective vaccine available, failure to protection because of vaccine-escape viral mutants in some population is also reported. moreover, all the currently approve ... | 2016 | 26561057 |
| care delivery and outcomes among us veterans with hepatitis b: a national cohort study. | previous studies have identified gaps in hepatitis b care. the objectives of this study were to evaluate the delivery of care among a national cohort of us veterans with chronic hepatitis b infection and examine risk factors for adverse clinical outcomes. we conducted a retrospective cohort study using the veterans health administration corporate data warehouse from 1999 to 2013 to evaluate (1) care delivery and (2) clinical outcomes such as hepatocellular carcinoma, hepatic decompensation, and ... | 2016 | 26561023 |
| a simple and rapid test-card method to detect hepatitis b surface antigen and antibody: potential application in young children and infants. | hepatitis b surface antigen (hbsag) and hepatitis b surface antibody (anti-hbs) were conventionally determined by enzyme immunoassays. we aimed to apply a rapid, simple, and accurate method to detect hbsag and its antibody. | 2016 | 26560182 |
| pharmacotherapeutic options for hepatitis b. | hepatitis b virus (hbv) is the driving force of disease progression in chronic hepatitis b. patients with active hbv replication and/or significant liver disease require timely treatment. currently, pegylated interferon-α (peg ifn), entecavir (etv) and tenofovir disoproxil fumarate (tdf) are the preferred first-line drugs. | 2016 | 26559942 |
| rare transmission of hepatitis b virus by dutch donors with occult infection. | to reduce the rate of transfusion-transmitted hepatitis b virus (hbv), hbv dna testing was introduced for all dutch blood donations in 2008, in addition to the existing screening for hbv surface antigen (hbsag). this study describes the lookback results for repeat donors with an "hbv dna-only" test result (hbv dna-positive and hbsag-negative). | 2016 | 26559665 |
| management of hepatitis b during pregnancy. | women of childbearing age or who are pregnant and have hepatitis b infection require specialized management both during and after pregnancy. effective maternal screening along with judicious use of available antivirals and immunoprophylaxis greatly reduces the perinatal transmission of hepatitis b virus (hbv) and dramatically declines the incidence and prevalence of chronic hepatitis b and its sequelae. | 2016 | 26559416 |
| comprehensive analyses of mutations and hepatitis b virus integration in hepatocellular carcinoma with clinicopathological features. | genetic alterations in specific genes are critical events in carcinogenesis and hepatocellular carcinoma (hcc) progression. however, the genetic alterations responsible for hcc development, progression, and survival are unclear. | 2016 | 26553052 |
| serum soluble urokinase-type plasminogen activator receptor and interferon-γ-induced protein 10 levels correlate with significant fibrosis in chronic hepatitis b. | hepatitis b virus (hbv) presents an important public health problem. liver biopsy is currently the gold standard for assessing the degree of intrahepatic inflammation and for staging liver fibrosis. however, the value of liver biopsies is limited by sampling errors, understaging and interobserver variability in interpretation. there is, therefore, a need to identify novel, non-invasive serologic biomarkers for the development of new predictive models of fibrosis. | 2016 | 26546355 |
| association of il-17a and il-17f gene polymorphisms with chronic hepatitis b and hepatitis b virus-related liver cirrhosis in a chinese population: a case-control study. | interleukin (il)-17 has been shown to play an important role in tissue inflammation and in the pathogenesis of immune-related liver damage. genetic variations in il-17 gene may be associated with the development of hepatitis b virus (hbv) infection. however, literature is scanty regarding their association. | 2016 | 26546176 |
| safety of abatacept in rheumatoid arthritis with serologic evidence of past or present hepatitis b virus infection. | rheumatoid arthritis (ra) with concomitant hepatitis b virus (hbv) infection represents a therapeutic challenge due to the risk of hbv reactivation under immunosuppressive treatment. to date there are few data coming from anecdotal case reports that concern hbv reactivation following treatment with abatacept. this observational retrospective study was aimed to assess the safety profile of abatacept in this particular clinical setting. | 2016 | 26555747 |
| a novel lipid nanoparticle adjuvant significantly enhances b cell and t cell responses to sub-unit vaccine antigens. | sub-unit vaccines are primarily designed to include antigens required to elicit protective immune responses and to be safer than whole-inactivated or live-attenuated vaccines. but their purity and inability to self-adjuvant often result in weaker immunogenicity. emerging evidence suggests that bio-engineered nanoparticles can be used as immunomodulatory adjuvants. therefore, in this study we explored the potential of novel merck-proprietary lipid nanoparticle (lnp) formulations to enhance immune ... | 2016 | 26555351 |
| evolution and mutations of hepatitis b virus quasispecies in genotype b and c during vertical transmission. | evolution patterns of hbv qs between genotype b and c during vertical transmission are not well understood. in this study, we enrolled 10 hbv infected mother-infant pairs (four pairs with genotype b, four pairs with genotype c, and two with co-infection) without anti-viral therapy. serum hbv dna of mothers and infants were sequenced, hbv qs complexity and diversity were analyzed, polymorphisms and mutation sites were recorded, and phylogenetic trees were performed. our result showed that the qs ... | 2016 | 26531675 |
| high titers of anti-hbs prevent rituximab-related viral reactivation in resolved hepatitis b patient with non-hodgkin's lymphoma. | rituximab, an anti-cd20 monoclonal antibody, is associated with an increased risk of hepatitis b virus (hbv) reactivation. this study aimed to determine the predictive factors for rituximab-related hbv reactivation in resolved hepatitis b patients, defined as hbsag-negative, anti-hbc-positive, and undetectable hbv dna. among 840 consecutive patients with cd20-positive b-cell lymphoma who received rituximab-based chemotherapy from 2003 through 2014 at seoul national university hospital, 732 patie ... | 2016 | 26531242 |
| reduced cerebral cortical thickness in non-cirrhotic patients with hepatitis c. | hepatitis c virus (hcv) infection is associated with fatigue, depression, and cognitive impairment even in the absence of severe liver fibrosis or cirrhosis. hcv has been hypothesised to cause neurodegenerative changes through low-grade neuroinflammation. our aim was to examine whether cortical thickness (cth) differs between chronic hcv patients and healthy controls, suggestive of cortical atrophy. in this case-control study 43 hcv patients without severe liver fibrosis, substance abuse, or com ... | 2016 | 26530221 |
| hepatitis b virus x protein activates notch signaling by its effects on notch1 and notch4 in human hepatocellular carcinoma. | deregulated expression of notch receptors and abnormal activity of notch signaling have been observed in a growing number of malignant tumors, however, the expression and activity of notch in hepatitis b virus (hbv)-associated hepatocellular carcinoma (hcc) and their relationship with hbv x protein (hbx) are still not fully elucidated. to address this, we examined the overall expression of notch receptors in hbv-associated hcc tissues, analyzed their relationship with hbx, and further investigat ... | 2016 | 26530164 |
| association between microrna-196a2 and microrna-146a polymorphisms and progression to cirrhosis and hepatocellular carcinoma in patients with viral hepatitis b. | micrornas (mirnas) are small noncoding rnas that have been implicated in mechanisms underlying various types of cancers including hepatocellular carcinoma (hcc). reports have indicated that single nucleotide polymorphisms in mirna-196a2 and mirna-146a genes may contribute to the risk of progression of hepatitis b virus (hbv) infection to cirrhosis and hcc. this study aimed to examine the effect of mirna-196a2 and mirna-146a polymorphisms on the progression of hbv infection to cirrhosis and/or hc ... | 2016 | 26529280 |
| the distribution of hepatitis b virus exposure and infection in a population-based sample of u.s. hispanic adults. | little is known regarding the prevalence and distribution of hepatitis b virus (hbv) infection in u.s. hispanics/latinos. we sought to determine the prevalence of hbv exposure (serum hbv core antibody; anti-hbc), active hbv infection (serum hbv surface antigen; hbsag), and vaccine-induced hbv immunity (antibody against hbv surface antigen; anti-hbs) in u.s. hispanics/latinos and consider how these data inform clinical screening recommendations. our analysis included 11,999 women and men of the h ... | 2016 | 26523403 |
| implementation of next-generation sequencing for hepatitis b virus resistance testing and genotyping in a clinical microbiology laboratory. | sanger sequencing or dna hybridization have been the primary modalities for hepatitis b (hbv) resistance testing and genotyping; however, there are limitations, such as low sensitivity and the inability to detect novel mutations. next-generation sequencing (ngs) for hbv can overcome these limitations, but there is limited guidance for clinical microbiology laboratories to validate this novel technology. in this study, we describe an approach to implementing deep pyrosequencing for hbv resistance ... | 2016 | 26537448 |
| xrcc1 rs25487 genetic variant and tp53 mutation at codon 249 predict clinical outcomes of hepatitis b virus-related hepatocellular carcinoma after hepatectomy: a cohort study for 10 years' follow up. | to investigate the effects of rs25487 (the dna repair gene: x-ray repair complementing defective repair in chinese hamster cells 1 [xrcc1]) and codon 249 mutation (tp53 gene) on clinical outcomes of post-hepatectomy hepatitis b virus (hbv)-related hcc. | 2016 | 26519348 |
| hepatitis b e antigen-positive and high levels of alanine aminotransferase are associated with prevalence of metabolic syndrome in chronic hbv patients. | the interactions between hepatitis b virus (hbv) infection and metabolic syndrome (ms) have not been elucidated. this study was aimed to investigate the relationship between metabolic profile and hbv infection. | 2016 | 26515918 |
| effect of tenofovir disoproxil fumarate on drug-resistant hbv clones. | tenofovir disoproxil fumarate (tdf) has been approved for chronic hepatitis b treatment, and favorable susceptibility of hepatitis b virus (hbv) has been indicated. however, differences in tdf susceptibility among hbv genotypes and drug-resistant strains are unclear. in this study, tdf susceptibilities between genotypes a and c were evaluated in vitro and in vivo using several drug-resistant hbv clones. | 2016 | 26515673 |
| the acceptable duration between occupational exposure to hepatitis b virus and hepatitis b immunoglobulin injection: results from a korean nationwide, multicenter study. | postexposure prophylaxis for occupational exposure to hepatitis b virus (hbv) plays an important role in the prevention of hbv infections in health care workers (hcws). we examined data concerning the acceptable duration between occupational exposure and administration of a hepatitis b immunoglobulin (hbig) injection in an occupational clinical setting. | 2016 | 26518500 |
| human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma. | the impact of human immunodeficiency virus (hiv) infection on patients undergoing liver transplantation (lt) for hepatocellular carcinoma (hcc) is uncertain. this study aimed to assess the outcome of a prospective spanish nationwide cohort of hiv-infected patients undergoing lt for hcc (2002-2014). these patients were matched (age, gender, year of lt, center, and hepatitis c virus (hcv) or hepatitis b virus infection) with non-hiv-infected controls (1:3 ratio). patients with incidental hcc were ... | 2016 | 26516761 |
| entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis b patients in the us - the enumerate study. | entecavir (etv) has been shown to be safe and efficacious in randomised controlled trials in highly selected patients with hepatitis b virus (hbv) infection. | 2016 | 26510638 |
| cost-effectiveness of active-passive prophylaxis and antiviral prophylaxis during pregnancy to prevent perinatal hepatitis b virus infection. | in an era of antiviral treatment, reexamination of the cost-effectiveness of strategies to prevent perinatal hepatitis b virus (hbv) transmission in the united states is needed. we used a decision tree and markov model to estimate the cost-effectiveness of the current u.s. strategy and two alternatives: (1) universal hepatitis b vaccination (hepb) strategy: no pregnant women are screened for hepatitis b surface antigen (hbsag). all infants receive hepb before hospital discharge; no infants recei ... | 2016 | 26509655 |
| a retrospective analysis of false-positive infectious screening results in blood donors. | false-positive infectious transfusion screening results remain a challenge with continued loss of both donors and blood products. we sought to identify associations between donor demographic characteristics (age, race, sex, education, first-time donor status) and testing false positive for viruses during routine blood donation screening. in addition the study assessed the prevalence of high-risk behaviors in false-positive donors. | 2016 | 26509432 |
| novel ph-sensitive multifunctional envelope-type nanodevice for sirna-based treatments for chronic hbv infection. | antiviral agents including entecavir (etv) suppress the replication of the hepatitis b virus (hbv) genome in human hepatocytes, but they do not reduce the abundance of viral proteins. the present study focused on effectively reducing viral protein levels. | 2016 | 26505121 |
| restoration of t cell function in chronic hepatitis b patients upon treatment with interferon based combination therapy. | chronic hepatitis b virus (hbv) infection is characterized by functional impairment of hbv-specific t cells. understanding the mechanisms behind t cell dysfunction and restoration is important for the development of optimal treatment strategies. | 2016 | 26505119 |
| post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis b-related hepatocellular carcinoma. | we investigated whether pre- or post-ablation serum alpha-foetoprotein (afp) and des-gamma-carboxy prothrombin (dcp) levels can predict prognosis in patients with curative radiofrequency ablation (rfa) for hepatitis b virus (hbv)-related hepatocellular carcinoma (hcc). | 2016 | 26503910 |
| liver capsule: entry and entry inhibition of hepatitis b virus and hepatitis delta virus into hepatocytes. | 2016 | 26502360 | |
| postoperative antiviral therapy with nucleos(t)ide analogs for patients with hepatitis b virus-related hepatocellular carcinoma. | 2016 | 26500197 | |
| text message reminders do not improve hepatitis b vaccination rates in an australian sexual health setting. | to evaluate the impact of text message reminders (short messaging service (sms)) on hepatitis b virus (hbv) vaccination completion among high risk sexual health center attendees. | 2016 | 26499103 |
| two years' experience of implementing molecular screening of hepatitis b virus, hepatitis c virus and human immunodeficiency virus 1, 2 in riyadh blood donors. | molecular screening technologies have improved blood safety by reducing the number of window-period transmissions relative to serological screening. in the two years following the introduction of molecular testing in king khalid university hospital, saudi arabia, 25,920 donor samples were screened in parallel by both serological and molecular techniques for hepatitis b virus (hbv), hepatitis c virus (hcv) and human immunodeficiency virus (hiv). no hcv or hiv nat yields were detected. however, mo ... | 2016 | 26497616 |
| a newly identified natural splice variant asn enhances hepatitis b virus amplification. | chronic hepatitis b virus (hbv) infection causes approximately one-third of all the cases of liver cirrhosis and more than three-quarters of hepatocellular carcinoma (hcc) worldwide. there are eight different genotypes (a-h) of hbv, among which b and c are the major types of hbv in china. there is a positive correlation between viral load and level of viral splicing variants and the high risk of hcc. the aim of this study was to investigate the splicing variants of hbv circulating in hcc patient ... | 2016 | 26501888 |
| control of hepatitis b virus infection in hematopoietic stem cell recipients after receiving grafts from vaccinated donors. | 2016 | 26501767 | |
| outcomes among children who received a kidney transplant in the united states from a hepatitis b core antibody-positive donor, 1995-2010. | accepting kidneys for transplant from donors with a history of hepatitis b virus infection may increase the availability of organs for those with end-stage kidney disease. in adult recipients, kidney transplants from hepatitis b virus core antibody-positive donors have resulted in favorable graft and patient survival rates. however, pediatric organ transplant recipients have developing immune systems and a higher risk of infectious complications than adults. accordingly, little is known about th ... | 2016 | 26501473 |
| increased intrahepatic quasispecies heterogeneity correlates with off-treatment sustained response to nucleos(t)ide analogues in e antigen-positive chronic hepatitis b patients. | finite treatment with nucleos(t)ide analogues (nas) remains a great challenge for chronic hepatitis b in the clinic. this study aimed to investigate the relationship between intrahepatic quasispecies heterogeneity and the nas off-treatment outcomes in a prospective cohort. eighteen hbeag-positive patients with chronic hepatitis b who achieved the cessation criteria underwent liver biopsy, and stopped treatment thereafter. patients were followed up prospectively for 1 year. the reverse transcript ... | 2016 | 26493847 |
| increased risk of infections and infection-related mortality in children undergoing haematopoietic stem cell transplantation compared to conventional anticancer therapy: a multicentre nationwide study. | this nationwide multicentre study analysed the epidemiology of bacterial, viral and fungal infections in paediatric haematopoietic stem cell transplantation (hsct) and paediatric haematology and oncology (pho) patients over a period of 24 consecutive months, including incidence, hazard risk and outcome of infections as well as occurrence of multidrug-resistant bacteria. during this period, 308 hscts were performed and 1768 children were newly diagnosed for malignancy. compared to pho, the risk i ... | 2016 | 26493843 |
| clinical course of hepatitis b surface antigen positive subjects following screening: a retrospective observational study from april 2008 to january 2013. | determination of the percentage of hepatitis b surface antigen (hbsag) positive participants who undergo screening and treatment may reduce the development of hepatocellular carcinoma. this study assessed the percentages of hbsag positive participants detected by free screening at medical institutions in saga prefecture who underwent detailed examinations and antiviral treatment. | 2016 | 26492344 |
| de novo hepatitis b prophylaxis with hepatitis b virus vaccine and hepatitis b immunoglobulin in pediatric recipients of core antibody-positive livers. | the use of hepatitis b core antibody-positive (hbcab+) grafts for liver transplantation (lt) has the potential to safely expand the donor pool, as long as proper prophylaxis against de novo hepatitis b (dnhb) is employed. the aim of this study was to characterize the longterm outcome of pediatric lt recipients of hbcab + liver grafts under a prophylaxis regimen against dnhb using hepatitis b virus (hbv) vaccine and hepatitis b immunoglobulin (hbig). from june 1996 to february 2013, 49 patients r ... | 2016 | 26600319 |
| comparison of efficacy and renal safety of telbivudine and entecavir in treatment-naive elderly patients with chronic hepatitis b. | data comparing the clinical outcomes of telbivudine (ldt) and entecavir (etv) in elderly patients with chronic hepatitis b are limited. | 2016 | 26587867 |
| intrahepatic hepatitis b virus replication and liver histology in subjects with occult hepatitis b infection. | we studied the intrahepatic hepatitis b virus (hbv) replicative status in 40 people with occult hepatitis b infection (obi) and 40 patients with chronic hepatitis b (chb). intrahepatic hbv dna, covalently closed circular dna (cccdna), and pre-genomic rna (pgrna) were quantified. patients with obi had median necroinflammation and fibrosis scores of 1 and 0, respectively. intrahepatic total hbv dna, cccdna and pgrna were detectable in 30 (77%), one (3%) and five (13%) of the participants with obi, ... | 2016 | 26585773 |
| combination therapy including cpg oligodeoxynucleotides and entecavir induces early viral response and enhanced inhibition of viral replication in a woodchuck model of chronic hepadnaviral infection. | cpg oligodeoxynucleotides (odns) stimulate immune cells via tlr9 and are potentially useful immunomodulators for the treatment of chronic viral infections. in the present study, different classes of cpgs were tested for their capacities for innate immune activation and antiviral activities in the woodchuck model. a class p cpg odn was found to stimulate interferon (ifn) production in woodchuck peripheral blood mononuclear cells (pbmcs) in vitro, and following subcutaneous administration in vivo, ... | 2016 | 26585244 |
| mirna-548p suppresses hepatitis b virus x protein associated hepatocellular carcinoma by downregulating oncoprotein hepatitis b x-interacting protein. | mir-548p is a recently identified and poorly characterized mirna. however, its role of mir-548p in tumorigenesis and progression remains poorly understood. here, we aimed to investigate the biofunction of mir-548p in hepatocellular carcinogenesis. | 2016 | 26583881 |
| peginterferon is superior to nucleos(t)ide analogues for prevention of hepatocellular carcinoma in chronic hepatitis b. | clinical factors associated with hepatocellular carcinoma (hcc) have been extensively studied in antiviral treatment-naive patients with chronic hepatitis b virus (hbv) infection but not in treatment-experienced patients. owing to the wide availability of antiviral agents that effectively suppress hbv replication, we investigated hcc risk factors in treatment-experienced patients. | 2016 | 26582959 |
| effect of a hepatitis b virus inhibitor, nz-4, on capsid formation. | during the hepatitis b virus (hbv) life cycle, nucleocapsid assembly is essential for hbv replication. both rna reverse transcription and dna replication occur within the hbv nucleocapsid. hbv nucleocapsid is consisted of core protein (hbcag), whose carboxy-terminal domain (ctd) contains an arg-rich domain (ard). the ard of hbcag does contribute to the encapsidation of pregenomic rna (pgrna). previously, we reported a small-molecule, nz-4, which dramatically reduced the hbv dna level in an in vi ... | 2016 | 26611395 |
| an evaluation of entecavir for the treatment of chronic hepatitis b infection in adults. | entecavir is a nucleoside analogue of 2'-deoxyguanosine whose intracellular triphosphate form inhibits replication of the hepatitis b virus. entecavir is recommended as a first-line monotherapy option for nucleos(t)ide-naïve patients with hbeag-positive or -negative chronic hepatitis b infection. entecavir has a three-step mechanism of action: it maintains viral suppression with a greater than 90% chance of undetectable hepatitis b virus dna during continuous therapy, improves liver histology, a ... | 2016 | 26610256 |
| geoepidemiology of hepatocellular carcinoma in the island of crete, greece. a possible role of pesticides. | geoepidemiological data of hepatocellular carcinoma (hcc) are lacking. crete has a genetically homogeneous population and is suitable for studies to identify a possible contribution of environmental factors in hcc. | 2016 | 26610175 |
| distinguished prognosis after hepatectomy of hbv-related hepatocellular carcinoma with or without cirrhosis: a long-term follow-up analysis. | conflicting results have often been observed for the prognosis of hepatocellular carcinoma (hcc) patients, but few studies have attempted to explore the reasons for the conflicting results. we aimed to distinguish the prognosis of patients with hcc with cirrhosis (hcc-c) and that of patients with hcc without cirrhosis (hcc-nc). | 2016 | 26607653 |
| incorporating serum level of hepatitis b surface antigen or omitting level of hepatitis b virus dna does not affect calculation of risk for hepatocellular carcinoma in patients without cirrhosis. | tests for hepatitis b virus (hbv) dna are expensive, and levels of hepatitis b surface antigen (hbsag) can help determine the risk for hepatocellular carcinoma (hcc) in patients with chronic hbv infection. we investigated how adding data to knowing the level of hbsag or excluding measurement of hbv dna affected the accuracy of the risk estimation for hepatocellular carcinoma in chronic hepatitis b (reach-b) scoring system in determining the risk for hcc. | 2016 | 26598229 |
| clearance of hbv dna in immunized children born to hbsag-positive mothers, years after being diagnosed with occult hbv infection. | in a previous study, we observed immunoprophylaxis failure due to occult hepatitis b virus (hbv) infection (obi) despite the presence of adequate levels of anti-hbs in 21 (28%) of 75 children born to hbsag-positive mothers. the aim of the study was to explore the maintenance of this cryptic condition in this population. of 21 obi-positive children, 17 were enrolled. hbv serological profiles were determined by enzyme-linked immunosorbent assay. highly sensitive real-time and standard pcr followed ... | 2016 | 26598112 |
| hbx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating erbb3. | poor prognosis of hepatitis b virus (hbv)-associated hepatocellular carcinoma (hcc) involves hbv x protein (hbx)-induced tumor progression. hbx also contributes to chemo-resistance via inducing the expressions of anti-apoptosis and multiple drug resistance genes. however, the impact of hbx expression on the therapeutic efficacy of various receptor tyrosine kinase inhibitors remains unknown. in this study, our data showed that hbx overexpression did not alter the cellular sensitivity of hcc cell ... | 2016 | 26595522 |
| evaluating hepatitis b virus reactivation during solid tumor chemotherapy: evidence to guide pretreatment hepatitis b screening and prophylaxis. | 2016 | 26595449 | |
| hepatitis b virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis. | solid tumor chemotherapy regimens pose a risk for hepatitis b virus (hbv) reactivation, but screening and antiviral prophylaxis remains controversial because of insufficient evidence. | 2016 | 26595058 |
| genetic variants in il12 influence both hepatitis b virus clearance and hbv-related hepatocellular carcinoma development in a chinese male population. | il12 plays a major role not only in inducing appropriate immune responses against viral infections (including hbv) but also in the antitumor immune response. this study was conducted to investigate the relationships of genetic variants in il12 with hepatitis b virus (hbv) clearance and development of hbv-related hepatocellular carcinoma (hcc). we genotyped three single nucleotide polymorphisms (snps) of the il12a (rs568406 and rs2243115) and il12b (rs3212227) in 395 hbv-positive hcc patients, 29 ... | 2016 | 26631030 |
| molecular epidemiology and genetic diversity of hepatitis b virus in ethiopia. | although hepatitis b virus (hbv) infection is hyperendemic in ethiopia and constitutes a major public health problem, little is known about its genetic diversity, genotypes, and circulation. the aim of this study was to determine the molecular epidemiology and genetic diversity of hbv in ethiopia, using 391 serum samples collected from hbsag-positive blood donors living in five different geographic regions. the hbv s/pol gene was amplified, sequenced, and hbv genotypes, subgenotypes, serotypes, ... | 2016 | 26629781 |
| hepatitis e virus infection and acute-on-chronic liver failure in west africa: a case-control study from the gambia. | in sub-saharan africa, it is unknown whether hepatitis e virus (hev) infection is a common precipitating event of acute-on-chronic liver failure (aclf). | 2016 | 26623967 |
| meta-analysis of the efficacy and safety of nucleotide/nucleoside analog monotherapy for hepatitis b virus-associated glomerulonephritis. | antiviral monotherapy is recommended for hepatitis b virus-associated glomerulonephritis (hbv-gn) treatment. although considered superior to interferon-î± in several respects, nucleotide/nucleoside analog (na) monotherapy has not been studied. this metaanalysis evaluates the efficacy and safety of na monotherapy for treating hbv-gn. | 2016 | 26636326 |
| hepatitis b virus (hbv) core-related antigen during nucleos(t)ide analog therapy is related to intra-hepatic hbv replication and development of hepatocellular carcinoma. | although nucleos(t)ide analog (na) therapy effectively reduces the hepatitis b virus (hbv) dna load in the serum of patients with chronic hepatitis b, it does not completely reduce the incidence of hepatocellular carcinoma (hcc). | 2016 | 26621908 |
| efficacy of tenofovir-based rescue therapy in patients with lamivudine-resistant hepatitis b virus: a systematic review and meta-analysis. | currently, there are no conclusive results on the efficacy of tenofovir disoproxil fumarate (tdf) monotherapy in chronic hepatitis b (chb) patients with lamivudine-resistant (lam-r). | 2016 | 26621535 |
| prevalence of hiv, hepatitis b, and hepatitis c in people with severe mental illness: a systematic review and meta-analysis. | although people with serious mental illnesses have a high risk of contracting blood-borne viral infections, sexual health has largely been neglected by researchers and policy makers involved in mental health. failure to address this shortcoming could increase morbidity and mortality as a result of undetected and untreated infection. we did a systematic review and meta-analysis to estimate the prevalence of blood-borne viral infection in people with serious mental illness. | 2016 | 26620388 |
| upregulation of pp2ac predicts poor prognosis and contributes to aggressiveness in hepatocellular carcinoma. | protein phosphatase 2a (pp2a) is a heterotrimeric protein phosphatase consisting of a 36-kd catalytic c subunit (pp2ac). this study aimed to explore the prognostic and biological significance of pp2ac in human hepatocellular carcinoma (hcc). high pp2ac expression was significantly (p < 0.01) associated with serum hepatitis b surface antigen positivity, serum hepatitis b e antigen positivity, liver cirrhosis, moderate to poor differentiation grade, advanced disease stage, intrahepatic metastasis, ... | 2016 | 26618405 |
| outcomes of hepatitis b surface antigenaemia in patients with incident end-stage renal disease. | hepatitis b virus (hbv) infection is an important risk factor for morbidity and mortality in the general population. however, limited data are available on the progression of hbv infection in patients with end-stage renal disease (esrd), and available data are controversial. therefore, we investigated the association between hepatitis b surface antigen (hbsag) seropositivity and mortality in patients with incident esrd. | 2016 | 26617162 |
| interaction of the hepatitis b virus x protein with the lysine methyltransferase set and mynd domain-containing 3 induces activator protein 1 activation. | hepatitis b virus (hbv) is a widespread human pathogen that often causes chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. the detailed mechanisms underlying hbv pathogenesis remain poorly understood. the hbv x protein (hbx) is a multifunctional regulator that modulates viral replication and host cell functions, such as cell cycle progression, apoptosis and protein degradation through interaction with a variety of host factors. recently, the nonstructural protein 5a (ns5a) of hepa ... | 2016 | 26616333 |
| evaluation of a novel chemiluminescent microplate enzyme immunoassay for hepatitis b surface antigen detection. | hepatitis b virus surface antigen (hbsag) is an important biomarker used in the diagnosis of hepatitis b virus (hbv) infection, but false-negative results are still reported in the detection of hbsag using commercial assays. in this study, we evaluated the qualitative properties of a novel hbsag chemiluminescence enzyme immunoassay (cleia) assay--wtultra. who standard sample dilution series and samples from low-level hbsag carriers (<1 ng/ml) were used to evaluate the sensitivity of the wtultra ... | 2016 | 26615806 |
| the lumipulse g hbsag-quant assay for screening and quantification of the hepatitis b surface antigen. | qualitative hbsag assay is used to screen hbv infection for decades. the utility of quantitative assay is also rejuvenated recently. we aimed to evaluate and compare the performance of a novel ultra-sensitive and quantitative assay, the lumipulse assay, with the architect and elecsys assays. as screening methods, specificity was compared using 2043 consecutive clinical routine samples. as quantitative assays, precision and accuracy were assessed. sera from 112 treatment-naïve chronic hepatitis b ... | 2016 | 26615803 |
| the covalently closed circular form of hepatitis b virus genome: is there now an end in "site"? | 2016 | 26615119 | |
| revised criteria for classification of the etiologies of acute liver failure and late-onset hepatic failure in japan: a report by the intractable hepato-biliary diseases study group of japan in 2015. | in 2011, the intractable liver diseases study group of japan, established novel diagnostic criteria for "acute liver failure ", and published the classification criteria for the etiologies of acute liver failure and late-onset hepatic failure (lohf) in 2013. according to this classification, hbv carriers showing acute hepatitis exacerbation were divided into 3 subgroups; asymptomatic or inactive hbv carriers without drug exposure, asymptomatic or inactive hbv carriers developing hbv reactivation ... | 2016 | 26615003 |
| annual influenza vaccination reduces total hospitalization in patients with chronic hepatitis b virus infection: a population-based analysis. | this study evaluated hospitalization and mortality in patients with chronic hepatitis b virus infection (hbv (+)) and matched comparison patients after stratifying the patients according to annual influenza vaccination (vaccine (+)). | 2016 | 26614589 |
| c-jun n-terminal kinase inhibitor favors transforming growth factor-β to antagonize hepatitis b virus x protein-induced cell growth promotion in hepatocellular carcinoma. | transforming growth factor (tgf)-β induces cell growth arrest in well-differentiated hepatocellular carcinoma (hcc) while hepatitis b virus x protein (hbx) minimizes the tumor suppression of tgf-β signaling in early chronic hepatitis b. however, how to reverse the oncogenic effect of hbx and sustain the tumor-suppressive action of tgf-β has yet to be investigated. the present study examined the effect of tgf-β and a c-jun n-terminal kinase (jnk) inhibitor on cell growth in hcc cells with forced ... | 2016 | 26648552 |
| evaluation of the dynamic pattern of viral evolution in patients with virological breakthrough during treatment with nucleoside/nucleotide analogs by ultra‑deep pyrosequencing. | virological breakthrough is a clinical manifestation in patients infected with chronic hepatitis b (chb), who undergo treatment with nucleoside/nucleotide analogs (nucs). the current understanding of the underlying mechanism of virological breakthrough is limited. ultra‑deep pyrosequencing (udps) is a novel and powerful tool used to investigate minor viral variants and viral evolution. the present study used udps to investigate the viral evolution pattern during virological breakthrough in patie ... | 2016 | 26648309 |
| correlation between th17 and ntreg cell frequencies and the stages of progression in chronic hepatitis b. | several studies have suggested that the balance of t helper 17 (th17) and natural regulatory t (ntreg) cells in the th17‑mediated immune response are critical in the pathogenesis of viral hepatitis. the aim of the present study was to examine the role of circulating th17 and ntreg cells in the disease progression of hepatitis b virus (hbv) infection. a total of 40 patients with chronic hbv (chb), 27 patients with hbv‑associated cirrhosis, 20 patients with hbv‑associated liver failure and 20 heal ... | 2016 | 26648026 |
| dendritic cells pulsed with hsp70 and hbxag induce specific antitumor immune responses in hepatitis b virus-associated hepatocellular carcinoma. | previous studies have drawn attention to dendritic cell (dc) vaccines; particularly the application of the tumor-associated antigen-targeted dc vaccine. the present study analyzed dcs derived from a normal individual and pulsed the cells with heat shock protein 70 peptide (hsp70) and/or hepatitis b virus x antigen (hbxag), a hepatocellular carcinoma (hcc)-associated antigen. it was then investigated whether this method of vaccination induced strong therapeutic antitumor immunity. the results rev ... | 2016 | 26647961 |
| hepatitis b virus induces hypoxia-inducible factor-2α expression through hepatitis b virus x protein. | a growing number of studies suggest that the hepatitis b virus x protein (hbx) enhances the protein stability of the hypoxia-inducible factor-1α (hif-1α). however, the relationship between hepatitis b virus (hbv), hbx and hypoxia-inducible factor-2α (hif-2α) has not yet been fully elucidated. immunohistochemical analysis was employed to detect the expression of hif-2α in normal liver, hbv-related chronic hepatitis, and hbv-related and non-hbv-related hepatocellular carcinoma (hcc) tissues. quant ... | 2016 | 26647960 |
| hepatitis b and cancer: a practical guide for the oncologist. | hepatitis b virus (hbv) infection is a worldwide disease associated with significant morbidity and mortality and after acute infection, hbv infection can persist in about 1-2% of immunocompetent hosts. chemotherapy-induced immunosuppression can lead to hbv reactivation and may cause discontinuation of anticancer treatment, fulminant hepatitis with liver failure and death. during immunosuppressive treatments such as chemotherapy, reactivation of hbv infection is a life-threatening complication th ... | 2016 | 26657667 |
| relationship between chronic hepatitis b and metabolic syndrome: a structural equation modeling approach. | investigate the nature of the relationship between chronic hepatitis b virus (hbv) infection and metabolic syndrome among nondiabetic adults. | 2016 | 26719030 |
| the na(+)-taurocholate cotransporting polypeptide traffics with the epidermal growth factor receptor. | na(+)-taurocholate cotransporting polypeptide (ntcp) mediates bile acid transport, also serving as the hepatitis b virus receptor. it traffics in vesicles along microtubules, requiring activity of protein kinase c (pkc)ζ for motility. we have now found that the epidermal growth factor receptor (egfr) is the target of pkcζ activity and that egfr and ntcp colocalize in vesicles. ntcp-containing vesicles that are not associated with egfr have reduced microtubule-based motility, consistent with intr ... | 2016 | 26650232 |
| luteolin inhibits hepatitis b virus replication through extracellular signal-regulated kinase-mediated down-regulation of hepatocyte nuclear factor 4α expression. | whether luteolin inhibits hbv replication has not been validated and the underlying mechanism of which has never been elucidated. in this study, we show that luteolin reduces hbv dna replication in hepg2.2.15 cells. luteolin effectively inhibited the expression of hepatocyte nuclear factor 4α (hnf4α) and its binding to the hbv promoters in hepg2.2.15 cells. while the extracellular signal-regulated kinase (erk) was activated by luteolin, inhibition of erk abolished luteolin-induced hnf4α suppress ... | 2016 | 26656210 |
| rates of hiv and hepatitis infections in clients entering heroin-assisted treatment between 2003 and 2013 and risk factors for hepatitis c infection. | we report on the rates of hepatitis a virus (hav), hepatitis b virus (hbv), hepatitis c virus (hcv) and human immunodeficiency virus (hiv) in 1,313 clients entering heroin-assisted treatment (hat) in switzerland from 2003 to 2013. we identify predictors of hcv infection. | 2016 | 26656112 |
| hla-a is a predictor of hepatitis b e antigen status in hiv-positive african adults. | outcomes of chronic infection with hepatitis b virus (hbv) are varied, with increased morbidity reported in the context of human immunodeficiency virus (hiv) coinfection. the factors driving different outcomes are not well understood, but there is increasing interest in an hla class i effect. we therefore studied the influence of hla class i on hbv in an african hiv-positive cohort. we demonstrated that virologic markers of hbv disease activity (hepatitis b e antigen status or hbv dna level) are ... | 2016 | 26655301 |
| property of hepatitis b virus replication in tupaia belangeri hepatocytes. | the northern treeshrew (tupaia belangeri) has been reported to be an effective candidate for animal infection model with hepatitis b virus (hbv). the objective of our study was to analyze the growth characteristics of hbv in tupaia hepatocytes and the host response to hbv infection. we established primary tupaia hepatocytes (3-6-week old tupaia) and infected them with hbv genotypes a, b and c, and all the genotypes proliferated as well as those in human primary hepatocytes (>10(5) copies/ml in c ... | 2016 | 26654952 |
| hiv-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies. | the long pursuit for a vaccine against human immunodeficiency virus 1 (hiv-1) has recently been boosted by a number of exciting developments. an hiv-1 subunit vaccine ideally should elicit potent broadly neutralizing antibodies (bnabs), but raising bnabs by vaccination has proved extremely difficult because of the characteristics of the hiv-1 envelope glycoprotein complex (env). however, the isolation of bnabs from hiv-1-infected patients demonstrates that the human humoral immune system is capa ... | 2016 | 26654478 |
| a label-free electrochemical immunosensor for hepatitis b based on hyaluronic acid-carbon nanotube hybrid film. | an electrochemical immunosensor developed for detection of antibodies to hepatitis b core protein (anti-hbc) is described. anti-hbc is the earliest serological marker from hepatitis b virus (hbv) infection, remaining all life after contact with virus, being considered the most important marker for uses in screening of blood bank. a nanohybrid surface assembled onto a glassy carbon electrode consisting of amino carbon nanotubes recovered by hyaluronic acid was used as sensing platform to detect t ... | 2016 | 26653442 |
| synergistic effect of magnetite and gold nanoparticles onto the response of a label-free impedimetric hepatitis b virus dna biosensor. | a magnetite and gold nanoparticle modified carbon paste electrode (cpe) was prepared for the immobilization of a thiol modified hepatitis b virus (hbv) probe dna and determination trace amount of target hbv dna. indeed, the sensing platform integrated two nanoparticles that had previously been employed individually in the dna biosensors. the proposed dna biosensor could measure target hbv dna virus concentration with a low detection limit of 3.1 (±0.1)×10-(13)m, which was greatly lower than the ... | 2016 | 26652432 |
| prospects and progress of dna vaccines for treating hepatitis b. | the hepatitis b virus (hbv) is a global cause of liver disease. the preventive hbv vaccine has effectively reduced the disease burden. however, an estimated 340 million chronic hbv cases are in need of treatment. current standard therapy for chronic hbv blocks reverse transcription. as this therapy blocks viral maturation and not viral protein expression, any immune inhibition exerted by these proteins will remain throughout therapy. this may help to explain why these drugs rarely induce off-the ... | 2016 | 26652035 |
| intranasal administration of novel chitosan nanoparticle/dna complexes induces antibody response to hepatitis b surface antigen in mice. | the generation of strong pathogen-specific immune responses at mucosal surfaces where hepatitis b virus (hbv) transmission can occur is still a major challenge. therefore, new vaccines are urgently needed in order to overcome the limitations of existing parenteral ones. recent studies show that this may be achieved by intranasal immunization. chitosan has gained attention as a nonviral gene delivery system; however, its use in vivo is limited due to low transfection efficiency mostly related to ... | 2016 | 26651533 |
| computerized physician order entry-based system improves hepatitis b virus screening in patients undergoing chemotherapy. | 2016 | 26644539 | |
| elevated serum soluble cd14 levels in chronic hbv infection are significantly associated with hbv-related hepatocellular carcinoma. | hepatitis b virus (hbv) infection is a major cause of chronic liver diseases including hepatocellular carcinoma (hcc). cd14 and its soluble form scd14 play important roles in immunity and are involved in the translocation of bacteria and their products which is related to the pathogenesis in chronic hbv infection. this study investigated serum scd14 levels in hbv chronically infected patients with various clinical diseases. serum scd14 levels in hbv patients were significantly elevated compared ... | 2016 | 26643893 |
| pin1 genetic polymorphisms and the susceptibility of hbv-related hepatocellular carcinoma in a guangxi population. | peptidyl-prolyl cis/trans isomerase nima-interacting 1 (pin1) plays a critical role in different signaling pathways, cell cycle progression and proliferation, and gene expression, and it has been found to overexpress in many tumor tissues. recently, researchers have found that pin1 gene polymorphisms may alter the function of protein and be associated with the risk of cancer. the present study analyzed three common polymorphisms in promoter regions (rs2233678 and rs2233679) and in exon2 (rs22336 ... | 2016 | 26643892 |
| chronic hepatitis b virus in the philippines. | multiple studies have shown a high prevalence of chronic hepatitis b (chb) infection in the philippines, not only in high-risk populations but also in the general population. the most recent national study estimated hbsag seroprevalence to be 16.7%, corresponding to an estimated 7.3 million chb adults. the factors underlying the high prevalence of chb and its sequelae include the inadequate use of vaccination for prevention and the lack of treatment for many filipinos. because without medical mo ... | 2016 | 26643262 |
| suitable hepatitis b vaccine for adult immunization in china. | the aim of this study was to evaluate, in adults, the immunogenicity of six hepatitis b vaccines with different doses or different manufacturers in the chinese market and to provide evidence to support adult hepatitis b vaccination. participants were randomly divided into six groups (i-vi). six vaccines (4 at 10 μg/dose and 2 at 20 μg/dose) were administered intramuscularly to healthy adults at 0, 1 and 6 month intervals. all participants (16-50 years) who were negative for any hepatitis b virus ... | 2016 | 26645972 |
| screening for transfusion transmissible infections using rapid diagnostic tests in africa: a potential hazard to blood safety? | rapid diagnostic tests (rdts) are routinely used in african blood centres. we analysed data from two cross-sectional studies representing 95 blood centres in 29 african countries. standardized panels of sera containing varying concentrations of anti-human immunodeficiency virus (hiv) antibodies (ab), hepatitis b virus antigen (hbsag) and antihepatitis c virus (hcv) ab were screened using routine operational testing procedures at the centres. sensitivity of detection using rdts was high for hiv a ... | 2016 | 26646317 |